



**REGION 11  
CHICAGO EMS SYSTEM  
MEDICATION TABLE**

Medication Name: Pralidoxime
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>GENERIC NAME</b>	<b>Pralidoxime</b>
<b>TRADE NAME</b>	2-PAM
<b>CLASSIFICATION</b>	Oxime, antidote for organophosphate and nerve agent poisoning
<b>DOSAGE FORMS</b>	<ul style="list-style-type: none"> <li>• Duodote: 600 mg IM</li> <li>• Mark 1 Kit: 600 mg IM</li> <li>• 20 ml vial containing 1 gram powder (50 mg/ml) (must be reconstituted with sterile water).</li> </ul>
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Binds to organophosphates and breaks alkyl phosphate-cholinesterase bond to restore activity of acetylcholinesterase</li> </ul>
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• For the management of toxicity caused by organophosphate insecticides and nerve agent poisoning (e.g. tabun, sarin, soman) including muscle fasciculations, nausea and vomiting, copious secretions, bradycardia, weakness, shortness of breath, unconsciousness, convulsions, paralysis and apnea.</li> <li>• MUST be used in conjunction with atropine</li> </ul>
<b>CONTRAINDICATIONS</b>	Documented hypersensitivity
<b>ADULT DOSE / ROUTE</b>	600 mg IM, may repeat x 2 for total of 1800 mg
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Pediatric nerve agent/organophosphate exposure dosages are not included in the Medication Table.</li> <li>• See Acetylcholinesterase Inhibitors Exposure – BLS/ALS Protocol</li> </ul>
<b>SIDE EFFECTS</b>	Hypertension, tachycardia, dizziness, blurred vision